Breast cancer is the most common malignancy in women in the United States in the year
2000. The proto-oncogene Her-2/neu (c-erb-B2) has become an increasingly important …

Background: The HER-2/neu oncogene and its p185 receptor protein are indicators of a more
aggressive form of breast cancer. HER-2/neu status guides Herceptin therapy, specifically …

HER-2/neu, also known as c-erbB-2/neu, is an oncogene located in chromosome 17 which
encodes HER-2/neu, a transmembrane protein belonging to the EGFR family. The external …

Objectives: To measure the frequency of estrogen receptor (ER), progesterone receptor (PR),
and Her 2 Neu positivity and to study their association with tumour characteristics and …

… agreement regarding their relationships with clinicopathological characteristics, as well as
the association between Her-2/neu and breast cancer survival, we combined FISH and CISH …

Background In the last several years, the study of cellular oncogenes has led to many
breakthroughs in molecular biology and medicine; and during that time, oncogenes have emerged …

Breast cancer is the most common malignancy in women with 180,000 new cases and 45,000
occurring annually in the USA. The lifetime risk for a woman for developing breast cancer …

… these technical considerations have impacted the sensitivity and specificity of HER-3/neu
detection has been most evident in the literature dealing with HER-2/neu and breast cancer. …

Background The HER2/neu proto-oncogene is frequently over-expressed in breast cancer
and serves as a biological target for trastuzumab therapy. However, there is no consensus …

There is sufficient evidence that human stomatin-like protein 2 (SLP-2) is a novel cancer-related
gene. Its protein is overexpressed in many human cancers. SLP-2 can contribute to the …